Neurona Therapeutics Presents Clinical Data for NRTX-1001 Regenerative Cell Therapy for Drug-Resistant Focal Epilepsy at American Epilepsy Society Annual Meeting
December 05, 2022 08:00 ET
|
Neurona Therapeutics
NRTX-1001 administration was well-tolerated, with notable seizure reduction reported in early data from the first two patients in Phase I/II clinical trial Additional preclinical data highlight...
Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data
November 21, 2022 08:00 ET
|
Neurona Therapeutics
Early data from the first two patients treated with NRTX-1001 report a trend toward seizure suppression and that administration of the cell treatment has been well-tolerated thus far Pioneering cell...
Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy
September 21, 2022 12:00 ET
|
Neurona Therapeutics
Clinical assessments three-months post-treatment report no serious adverse events and reduced seizure frequency to date in first trial participant Data Safety Monitoring Board clears advancement of...
Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy
June 29, 2022 07:00 ET
|
Neurona Therapeutics
Neurona has initiated dosing of a first-ever regenerative human cell therapy candidate in a Phase 1/2 clinical trial for epilepsy Pioneering cell therapy approach could revolutionize the treatment of...
Neurona Therapeutics to Present Preclinical Data Supporting Regenerative Cell Therapy, NRTX-1001, in Clinical Development for Chronic Focal Epilepsy, at the ISSCR 2022 Annual Meeting
June 17, 2022 16:55 ET
|
Neurona Therapeutics
Oral presentation will outline design of first ever Phase 1/2 clinical trial of regenerative human cell therapy in epilepsy Presentations will detail single-cell transcriptomic profiling of NRTX-1001...
Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy
May 26, 2022 16:00 ET
|
Neurona Therapeutics
CIRM grant awarded to accelerate clinical trial of NRTX-1001, a promising regenerative neuronal cell therapy in adults with drug-resistant seizures NRTX-1001 is the first human cell therapy candidate...
Neurona Therapeutics to Present at the Locust Walk Stem Cell Tx Conference
April 04, 2022 16:01 ET
|
Neurona Therapeutics
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies to treat chronic neurological disorders, today...
Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy
April 01, 2022 08:00 ET
|
Neurona Therapeutics
SAN FRANCISCO, April 01, 2022 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders,...
Neurona Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
January 05, 2022 16:02 ET
|
Neurona Therapeutics
SAN FRANCISCO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological disorders,...
Neurona Therapeutics Announces C-Suite Leadership Team
December 13, 2021 08:00 ET
|
Neurona Therapeutics
SAN FRANCISCO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological disorders,...